Skip to content

MDMA and psychedelic-assisted therapy: all studies

Page 4 of 15: studies 31 to 40 of 143, newest first. Back to the MDMA and psychedelic-assisted therapy overview

Research

The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.

Journal of Affective Disorders January 15, 2025 Jia-Ru Li, Kuo-Tung Chiang, Yu-Chen Kao et al. 1 citation

Different study designs of psychedelic trials may impact the blinding and expectance, leading to biased treatment effects. This study aimed to examine the association between antidepressant efficacy and study designs in psychedelic trials. Six databases were systematically searched. Eligible trials were required to investigate the efficacy of psychedelics (psilocybin, lysergic acid diethylamide...

The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.

Therapeutic Advances in Psychopharmacology 2025 Diana McHerron, Michaela Barber, Rachel Ham et al.

Physical touch is often included as a supportive or therapeutic tool in psychedelic-assisted therapy (PAT), involving instrumental forms of physical contact, supportive touch and somatic techniques. However, participants under the influence of psychedelics have reduced capacity to provide consent, are more suggestible and may experience and interpret therapeutic touch in ways they did not...

MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: Systematic literature review.

PLoS One 2025 Filip Stanicic, Vladimir Zah, Dimitrije Grbic et al. 5 citations

3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) is currently being evaluated for treatment of patients with moderate or higher severity post-traumatic stress disorder (PTSD). To provide a comprehensive summary of investigational MDMA-AT and current treatments for PTSD. A search was conducted in PubMed and Embase (December 20, 2023). Populations included adults with chronic,...

Post-traumatic stress disorder in psychedelic research.

International review of neurobiology 2025 Tijmen Bostoen, Stephan Tap, Joost J. Breeksema et al. 1 citation

Post-Traumatic Stress Disorder (PTSD) is a severe psychiatric condition that develops after exposure to trauma such as combat, natural disasters, or assault. It is characterized by re-experiencing trauma, avoidance, hyperarousal, and negative alterations in cognition and mood. Since its formal inclusion in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-III in 1980, PTSD has...

Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach.

Frontiers in Psychiatry 2025 Alexa E Albert, Anthony L. Back 5 citations

Pathological narcissism (PN) is a complex, treatment-resistant disorder characterized by unstable self-esteem that fluctuates between grandiosity and vulnerability, complicating the formation of a stable self-image. With few empirically supported therapies, treatment has traditionally relied on long-term psychoanalytic approaches, but these often face high attrition. Recent research suggests a...

DOI: 10.3389/fpsyt.2025.1529427 (opens in new tab) Full text (opens in new tab) Psychedelic therapy 3,4-Methylenedioxymethamphetamine MDMA Developmental trauma Early relational trauma +7

Treatment of neuropathic pain with repeated low-dose MDMA: a case report.

Frontiers in Psychiatry 2025 Peter Gasser, Matthias E. Liechti, Friederike Holze 2 citations

A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium to high doses of lysergic acid diethylamide (LSD) and high doses and microdoses of methylenedioxymethamphetamine (MDMA). At the beginning of treatment, the patient did not experience any acute subjective effects of LSD at a dose of 200 µg. After...

Informed Consent in Psychedelic-Assisted Therapy.

Current Topics in Behavioral Neurosciences December 31, 2024 Mazdak M. Bradberry, Paul S. Appelbaum, Natalie Gukasyan 7 citations

Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed "psychedelics," for therapeutic purposes in...

MDMA for PTSD and beyond: a new paradigm brings hope.

Front Hum Neurosci December 11, 2024 Scott Shannon, Jamarie Geller 3 citations

Introduction We are experiencing a mental health crisis of unprecedented proportions. Over the last two decades this crisis grew from a perfect storm of rising insurance deductibles, escalating social stressors, the COVID-19 pandemic, and a critical workforce deficiency. Perhaps no mental health arena has a greater shortfall of effective treatment options than Post-traumatic Stress Disorder...

MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).

Neuropsychopharmacology Reports December 1, 2024 Ghada Shahrour, Kainat Sohail, Safa Elrais et al. 21 citations

Post-traumatic stress disorder (PTSD) is a mental health disorder resulting from exposure to traumatic events, manifesting in various debilitating symptoms. Despite available treatments, many individuals experience inadequate response or significant side effects. Previous reviews suggest promising outcomes with MDMA-assisted psychotherapy (MDMA-AT), but limitations prompt the need for a...

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.

Scientific Reports November 14, 2024 Erin Wang, David S. Mathai, Natalie Gukasyan et al. 18 citations

Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumatic stress disorder. Psilocybin and MDMA may become approved medicines in the coming decade. This study assessed knowledge and attitudes regarding PAT among 879 U.S. healthcare professionals via anonymous online survey. Multivariable linear regression...